The present invention relates to an ear-cleansing agent for companion animals and a method of manufacturing the same. More particularly, the present invention relates to an ear-cleansing agent for companion animals, which includes distilled Chamaecyparis obtusa water extracted from Chamaecyparis obtusa trees so as to enable antibacterial action, deodorization, and exfoliation and which does not include a surfactant so that the skin is not irritated even when the ear-cleansing agent is not washed away using water, and a method of manufacturing the same.

The present invention relates to an ear-cleansing agent for companion animals and a method of manufacturing the same. More particularly, the present invention relates to an ear-cleansing agent for companion animals, which includes distilled Chamaecyparis obtusa water extracted from Chamaecyparis obtusa trees so as to enable antibacterial action, deodorization, and exfoliation and which does not include a surfactant so that the skin is not irritated even when the ear-cleansing agent is not washed away using water, and a method of manufacturing the same.

Provided are aqueous Alerce (Fitzroya cupressoides) cell extracts, which may be obtained from in vitro cultures of Alerce cells. The aqueous Alerce cell extracts promote cell regeneration, and therefore have anti-aging properties. The Alerce cell extracts have been found to have no toxic effects on human cells, and have been found to not boost skin cancer cells. Such extracts may be used in pharmaceutical or cosmetic formulations for skin care, especially to promote regeneration and/or anti-aging of the skin.

Provided are aqueous Alerce (Fitzroya cupressoides) cell extracts, which may be obtained from in vitro cultures of Alerce cells. The aqueous Alerce cell extracts promote cell regeneration, and therefore have anti-aging properties. The Alerce cell extracts have been found to have no toxic effects on human cells, and have been found to not boost skin cancer cells. Such extracts may be used in pharmaceutical or cosmetic formulations for skin care, especially to promote regeneration and/or anti-aging of the skin.

Disclosed herein are compositions, delivery devices and methods for feminine health. A delivery device for feminine health can include a feminine hygiene product including an absorbent substrate and a composition absorbed onto the absorbent substrate for placement against a vulva, inserted into a vagina, or both. The composition can include a continuous phase and a dispersed phase dispersed throughout the continuous phase forming a fluid suspension. The continuous phase can include a solvent of one or more essential oils, one or more lubricants, or a combination thereof. The continuous phase can include one or more solutes dissolved in the solvent including one or more fat-soluble vitamins. The dispersed phase can include a pH-balancing agent, a dietary mineral, an absorbent, one or more water-soluble vitamins, or a combination thereof.

Disclosed herein are compositions, delivery devices and methods for feminine health. A delivery device for feminine health can include a feminine hygiene product including an absorbent substrate and a composition absorbed onto the absorbent substrate for placement against a vulva, inserted into a vagina, or both. The composition can include a continuous phase and a dispersed phase dispersed throughout the continuous phase forming a fluid suspension. The continuous phase can include a solvent of one or more essential oils, one or more lubricants, or a combination thereof. The continuous phase can include one or more solutes dissolved in the solvent including one or more fat-soluble vitamins. The dispersed phase can include a pH-balancing agent, a dietary mineral, an absorbent, one or more water-soluble vitamins, or a combination thereof.

Disclosed herein are compositions, delivery devices and methods for feminine health. A delivery device for feminine health can include a feminine hygiene product including an absorbent substrate and a composition absorbed onto the absorbent substrate for placement against a vulva, inserted into a vagina, or both. The composition can include a continuous phase and a dispersed phase dispersed throughout the continuous phase forming a fluid suspension. The continuous phase can include a solvent of one or more essential oils, one or more lubricants, or a combination thereof. The continuous phase can include one or more solutes dissolved in the solvent including one or more fat-soluble vitamins. The dispersed phase can include a pH-balancing agent, a dietary mineral, an absorbent, one or more water-soluble vitamins, or a combination thereof.

Covid-19 binding aerosols are provided. The Covid-19 binding aerosols include Fe.sub.3O.sub.4 microparticles, at least one organoselenium compound, at least one essential oil, and incense. The Covid-19 binding aerosols may be formulated for use in any product that is capable of emitting aerosols, including but not limited to as air fresheners, as incense, or the like. The Fe.sub.3O.sub.4 microparticles may have an average size of 5,000 nm-10,000 nm (between 5-10 μm). The Covid-19 binding aerosols are formulated as aerosol compositions having an average size of greater than 60 μm-100 μm to ensure effective binding to virions.

Covid-19 binding aerosols are provided. The Covid-19 binding aerosols include Fe.sub.3O.sub.4 microparticles, at least one organoselenium compound, at least one essential oil, and incense. The Covid-19 binding aerosols may be formulated for use in any product that is capable of emitting aerosols, including but not limited to as air fresheners, as incense, or the like. The Fe.sub.3O.sub.4 microparticles may have an average size of 5,000 nm-10,000 nm (between 5-10 μm). The Covid-19 binding aerosols are formulated as aerosol compositions having an average size of greater than 60 μm-100 μm to ensure effective binding to virions.

Covid-19 binding aerosols are provided. The Covid-19 binding aerosols include Fe.sub.3O.sub.4 microparticles, at least one organoselenium compound, at least one essential oil, and incense. The Covid-19 binding aerosols may be formulated for use in any product that is capable of emitting aerosols, including but not limited to as air fresheners, as incense, or the like. The Fe.sub.3O.sub.4 microparticles may have an average size of 5,000 nm-10,000 nm (between 5-10 μm). The Covid-19 binding aerosols are formulated as aerosol compositions having an average size of greater than 60 μm-100 μm to ensure effective binding to virions.